2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2091

Plasma Microparticle Protein Features Distinctively Classify Systemic Lupus Erythematosus and Systemic Sclerosis and Their Clinical Phenotype
Abstract Number: 2745

Plasma of Patients with Active Behçet´s Disease (BD) Increases Neutrophil Extracellular Trap Formation, Oxidative Metabolism and NADPH-Oxidase Expression in Normal and BD Neutrophils, and Carries Several Neutrophil Stimulating Factors
Abstract Number: 1779

Plasmapheresis Therapy in ANCA-Associated Vasculitides: A Single-Center Retrospective Analysis of Renal Outcome and Mortality
Abstract Number: 1727

Poly(ADP-ribose) Polymerase-1 (PARP-1) Suppresses the Profibrotic Effects of Transforming Growth Factor â in Systemic Sclerosis
Abstract Number: 2958

Polygenic Analysis of Transport, Metabolism and Immune Related Genomic Compartments in Serum Urate and Gout
Abstract Number: 2742

Polymorphisms in the Slam Family of Molecules Play a Role in the Development and Function of Invariant Natural Killer T Cells in New Zealand Black Mice
Abstract Number: 2171

Polymorphisms in theÂ FCN1Â Gene Coding for M-Ficolin Are Associated with Disease Activity, Radiographic Damage and Are the Strongest Predictors of DAS28 Remission in 180 DMARD naÃ¯ve Early Rheumatoid Arthritis Patients
Abstract Number: 2770

Polymyalgia Rheumatica Relapse and “Silence” Large Vessel Vasculitis. Is There Any Association?
Abstract Number: 893

Polysymptomatic Distress Categories for Clinical and Research Use
Abstract Number: 903

Poor Adherence to Medications for Systemic Lupus Erythematosus Predicts Higher Health Care Utilization in U.S. Medicaid Beneficiaries
Abstract Number: 1355

Population Management of Rheumatoid Arthritis (RA) in Rheumatology Practices: A Quality Improvement Project
Abstract Number: 1475

Porphyromonas Gingivalis and Bone Turnover Biomarkers in Rheumatoid Arthritis
Abstract Number: 168

Positive Association Between Tomato Consumption and Serum Urate: Investigating an Anecdotal Trigger of Gout Flares
Abstract Number: 2304

Positive HLA-B27 in Juvenile Spondyloarthritis Is Associated to Early Sacroiliitis and Progression to Ankylosing Spondylitis
Abstract Number: 2613

Positive Spine MRI for Inflammation Predicts Radiographic Progression in Patients with Ankylosing Spondylitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].